Blood-brain barrier dysfunction as a potential therapeutic target for neurodegenerative disorders
- PMID: 34028650
- DOI: 10.1007/s12272-021-01332-8
Blood-brain barrier dysfunction as a potential therapeutic target for neurodegenerative disorders
Abstract
The blood-brain barrier (BBB) is composed of specific tight junction proteins and transporters expressed on the lining of endothelial cells of the vasculature in the brain. The structural and functional integrity of the BBB is one of the most critical factors for maintaining brain homeostasis and is mainly regulated by complex interactions between various cell types, such as endothelial cells, pericytes, and astrocytes, which are shaped by their differential responses to changes in microenvironments. Alterations in these cellular components have been implicated in neurodegenerative disorders. Although it has long been considered that BBB dysfunction is a mere ramification of pathological phenomena, emerging evidence supports its critical role in the pathogenesis of various disorders. In epilepsy, heightened BBB permeability has been found to be associated with increased occurrence of spontaneous seizures. Additionally, exaggerated inflammatory responses significantly correlate with increased BBB permeability during healthy aging. Furthermore, it has been previously reported that BBB disruption can be an early marker for predicting cognitive impairment in the progression of Alzheimer's disease. We herein review a potential role of the major cellular components of the BBB, with a focus on the contribution of BBB disruption, in neurodegenerative disease progression.
Keywords: Aging; Alzheimer’s disease; Epilepsy; Extracellular matrix; Inflammation; Neuroglial interaction; Neurovascular unit.
Similar articles
-
Age-associated physiological and pathological changes at the blood-brain barrier: A review.J Cereb Blood Flow Metab. 2017 Jan;37(1):4-24. doi: 10.1177/0271678X16679420. Epub 2016 Nov 11. J Cereb Blood Flow Metab. 2017. PMID: 27837191 Free PMC article. Review.
-
Understanding the Blood-Brain Barrier: From Physiology to Pathology.Adv Exp Med Biol. 2025;1477:1-33. doi: 10.1007/978-3-031-89525-8_1. Adv Exp Med Biol. 2025. PMID: 40442381 Review.
-
"Nattokinase as a potential therapeutic agent for preventing blood-brain barrier dysfunction in neurodegenerative disorders".Brain Res. 2025 Feb 15;1849:149352. doi: 10.1016/j.brainres.2024.149352. Epub 2024 Nov 26. Brain Res. 2025. PMID: 39592088 Review.
-
P7C3-A20 treatment one year after TBI in mice repairs the blood-brain barrier, arrests chronic neurodegeneration, and restores cognition.Proc Natl Acad Sci U S A. 2020 Nov 3;117(44):27667-27675. doi: 10.1073/pnas.2010430117. Epub 2020 Oct 21. Proc Natl Acad Sci U S A. 2020. PMID: 33087571 Free PMC article.
-
Vascular Cell Senescence Contributes to Blood-Brain Barrier Breakdown.Stroke. 2016 Apr;47(4):1068-77. doi: 10.1161/STROKEAHA.115.010835. Epub 2016 Feb 16. Stroke. 2016. PMID: 26883501 Free PMC article.
Cited by
-
Sphingosine 1-phosphate receptor 1 regulates blood-brain barrier permeability in epileptic mice.Neural Regen Res. 2023 Aug;18(8):1763-1769. doi: 10.4103/1673-5374.360263. Neural Regen Res. 2023. PMID: 36751803 Free PMC article.
-
The Construction of a Multidomain Risk Model of Alzheimer's Disease and Related Dementias.J Alzheimers Dis. 2023;96(2):535-550. doi: 10.3233/JAD-221292. J Alzheimers Dis. 2023. PMID: 37840484 Free PMC article.
-
Glutamate Efflux across the Blood-Brain Barrier: New Perspectives on the Relationship between Depression and the Glutamatergic System.Metabolites. 2022 May 20;12(5):459. doi: 10.3390/metabo12050459. Metabolites. 2022. PMID: 35629963 Free PMC article. Review.
-
The Crucial Role of the Blood-Brain Barrier in Neurodegenerative Diseases: Mechanisms of Disruption and Therapeutic Implications.J Clin Med. 2025 Jan 9;14(2):386. doi: 10.3390/jcm14020386. J Clin Med. 2025. PMID: 39860392 Free PMC article. Review.
-
T Cells Trafficking into the Brain in Aging and Alzheimer's Disease.J Neuroimmune Pharmacol. 2024 Aug 24;19(1):47. doi: 10.1007/s11481-024-10147-5. J Neuroimmune Pharmacol. 2024. PMID: 39180590 Review.
References
-
- Abbott NJ (2002) Astrocyte–endothelial interactions and blood–brain barrier permeability. J Anat 200(5):523–534. https://doi.org/10.1046/j.1469-7580.2002.00064.x - DOI
-
- Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL (2000) Inflammation and Alzheimer’s disease. Neurobiol Aging 21(3):383–421. https://doi.org/10.1016/s0197-4580(00)00124-x - DOI - PubMed - PMC
-
- Alvarez XA, Alvarez I, Aleixandre M, Linares C, Muresanu D, Winter S, Moessler H (2018) Severity-related increase and cognitive correlates of serum VEGF levels in Alzheimer’s disease ApoE4 carriers. J Alzheimers Dis 63(3):1003–1013. https://doi.org/10.3233/JAD-160477 - DOI - PubMed
-
- Amor S, Peferoen LA, Vogel DY, Breur M, van der Valk P, Baker D, van Noort JM (2014) Inflammation in neurodegenerative diseases–an update. Immunology 142(2):151–166. https://doi.org/10.1111/imm.12233 - DOI - PubMed - PMC
-
- Araque A, Sanzgiri RP, Parpura V, Haydon PG (1998) Calcium elevation in astrocytes causes an NMDA receptor-dependent increase in the frequency of miniature synaptic currents in cultured hippocampal neurons. J Neurosci 18(17):6822–6829. https://doi.org/10.1523/JNEUROSCI.18-17-06822.1998 - DOI - PubMed - PMC
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical